Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 116, Issue , 2017, Pages 68-81

  Chan, Wing lok ^a   Yuen, Kwok keung ^a   Siu, Steven Wai kwan ^a   Lam, Ka on ^b   Kwong, Dora Lai wan ^b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemotherapy; Gastric cancer; Metastatic; Palliative care; Targeted therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; APATINIB; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOCETAXEL; EVEROLIMUS; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; LACTATE DEHYDROGENASE; REGORAFENIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; BACKACHE; BEST SUPPORTIVE CARE; CANCER SURVIVAL; CONSTIPATION; COUGHING; DIARRHEA; DYSPNEA; FATIGUE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOPROTEINEMIA; INSOMNIA; LEUKOPENIA; META ANALYSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THIRD LINE SYSTEMIC TREATMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; PALLIATIVE THERAPY; STOMACH TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; PALLIATIVE CARE; PATIENT-CENTERED CARE; QUALITY OF LIFE; STOMACH NEOPLASMS;

EID: 85024923239     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2017.05.002     Document Type: Review

References (38)

1. Bang, Y.J., Chung, H.C., Shankaran, V., Geva, R., Catenacci, D.V.T., Gupta, S., Eder, J.P., Berger, R., Gonzalez, E.J., Ray, A., et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J. Clin. Oncol., 33(Suppl. 15), 2015, 4001.
2. Blazeby, J.M., Conroy, T., Bottomley, A., Vickery, C., Arraras, J., Sezer, O., et al. European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur. J. Cancer 40:October (15) (2004), 2260–2268.
3. Cunningham, D., Tebbutt, N.C., Davidenko, I., Murad, A.M., Al-Batran, S.-E., Ilson, D.H., et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J. Clin. Oncol., 33(Suppl. 15), 2015, 4000.
4. Doi, T., Kang, Y.K., Muro, K., Jiang, Y., Jain, R.K., Lizambri, R., A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the RILOMET-2 trial. J. Clin. Oncol., 33(Suppl. 15), 2015, TPS226.
5. Gallo, A., Cha, C., Updates on esophageal and gastric cancers. World J. Gastroenterol.(12), 2006, 3237–3242.
6. Gunderson, L.L., Gastric cancer – patterns of relapse after surgical resection. Semin. Radiat. Oncol. 12 (2002), 150–161.
7. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. Higgins, J.P.T., Green, S., (eds.), 2011, The Cochrane Collaboration Available from www.cochrane-handbook.org.
8. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
9. Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG trial. J. Clin. Oncol. 31:December (35) (2013), 4438–4444, 10.1200/JCO.2012.48.5805 Epub 2013 November 4.
10. Kang, J.H., Lee, S.I., Lim do, H., Park, K.W., Oh, S.Y., Kwon, H.C., et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Clin. Oncol. 30:May (13) (2012), 1513–1518, 10.1200/JCO.2011.39.4585 Epub 2012 March 12.
11. Kang, E.J., Im, S.A., Oh, D.Y., Han, S.W., Kim, J.S., Choi, I.S., et al. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. Gastric Cancer 16:October (4) (2013), 581–589, 10.1007/s10120-012-0227-5 Epub 2012 December 25.
12. Kang, Y.K., Satoh, T., Ryu, M.H., et al. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): a double-blinded, randomized, phase III trial. J. Clin. Oncol., 35(Suppl), 2017, 4S Abstract 2.
13. Kim, S.G., Oh, S.Y., Kwon, H.C., Lee, S., Kim, J.H., Kim, S.H., et al. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn. J. Clin. Oncol. 37:October (10) (2007), 744–749 Epub 2007 October 8.
14. Kim, H.S., Kim, H.J., Kim, S.Y., Kim, T.Y., Lee, K.W., Baek, S.K., et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann. Oncol. 24:November (11) (2013), 2850–2854, 10.1093/annonc/mdt351 Epub 2013 August 13.
15. Lacovelli, R., Pietrantonio, F., Farcomeni, A., Maggi, C., Palazzo, A., Ricchini, F., et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLOS ONE, 9(September (9)), 2014, e108940, 10.1371/journal.pone.0108940 eCollection 2014.
16. Lee, J.L., Ryu, M.H., Chang, H.M., Kim, T.W., Yook, J.H., Oh, S.T., et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother. Pharmacol. 61:April (4) (2008), 631–637 Epub 2007 May 23.
17. Lee, M.J., Hwang, I.G., Jang, J.S., Choi, J.H., Park, B.B., Chang, M.H., et al. Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies. Cancer Res. Treat. 44:December (4) (2012), 235–241.
18. Lee, J.H., Kim, S.H., Oh, S.Y., Lee, S., Lee, H., Lee, H.J., et al. Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer. Korean J. Intern. Med. 28:May (3) (2013), 314–321, 10.3904/kjim.2013.28.3.314 Epub 2013 May 1.
19. Li, J., Qin, S., Xu, J., Guo, W., Xiong, J., Bai, Y., et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J. Clin. Oncol. 31:26 (2013), 3219–3225.
20. Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 34:May (13) (2016), 1448–1454, 10.1200/JCO.2015.63.5995 Epub 2016 February 16.
21. Liepa, A., Mitchell, S., Batson, S., Jen, M.H., Davie, A., Taipale, K., Hess, L., Systematic review and meta-analysis of recommended second-line therapies for advanced gastric cancer (GC). Eur. J. Cancer, 2015 Conference: European Cancer Congress 2015, ECC 2015 Vienna Austria. Conference Start: 20150925 Conference End: 20150929. Conference Publication: (var.pagings). 51 (pp S437), 2015. Date of Publication: September 2015.
22. Moon, Y.W., Rha, S.Y., Jeung, H.C., Kim, C., Hong, M.H., Chang, H., et al. Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother. Pharmacol. 66:September (4) (2010), 797–805, 10.1007/s00280-010-1295-z Epub 2010 March 11.
23. NCT02494583: Study of. 2015 Available from: https://clinicaltrials.gov/ct2/show/NCT02494583?term=keynote-062&rank=1.
24. NCT02625610: Avelumab in. 2015 Available from: https://clinicaltrials.gov/ct2/show/NCT02625610?term=JAVELIN+Gastric+100&rank=1.
25. NCT02625623: Avelumab in. 2015 Available from: https://clinicaltrials.gov/ct2/show/NCT02625623?term=JAVELIN+Gastric+100&rank=2.
26. NCT02773524: A. 2016 Available from: https://clinicaltrials.gov/ct2/show/NCT02773524?term=integrateII&rank=1.
27. NCT02370498: A. 2016 Available from: http://www.clinicaltrials.gov/ct/show/NCT02370498.
28. Ohtsu, A., Ajani, J.A., Bai, Y.X., Bang, Y.J., Chung, H.C., Pan, H.M., et al. Everolimus for previously treated advanced gastric cancer: results of the randomized double-blind phase III GRANITE-1 study. J. Clin. Oncol. 31:November (31) (2013), 3935–3943, 10.1200/JCO.2012.48.3552 Epub 2013 September 16.
29. Park, S.H., Choi, E.Y., Bang, S.M., Cho, E.K., Lee, J.H., Shin, D.B., et al. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs 16:July (6) (2005), 621–625.
30. Pavlakis, N., Sjoquist, K.M., Tsobanis, E., Martin, A.J., Kang, Y.-K., Bang, J., et al. INTEGRATE: a randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): a study by the Australasian Gastrointestinal Trials Group (AGITG)-final overall and subgroup results. J. Clin. Oncol., 2015 Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. Conference Start: 20150529 Conference End: 20150602. Conference Publication: (var.pagings). 33 (15 SUPPL. 1) (no pagination), 2015. Date of Publication: 20 May 2015.
31. Scott, N.W., Fayers, P.M., Aaronson, N.K., Bottomley, A., de Graeff, A., Groenvold, M., et al. EORTC Quality of Life Group. EORTC QLQ-C30 Reference Values. 2008, EORTC Quality of Life Group Publications, Brussels Available from http://groups.eortc.be/qol/sites/default/files/img/newsletter/reference_values_manual2008.pdf.
32. Shah, M.A., Bang, Y.J., Lordick, F., Tabernero, J., Chen, M., Hack, S.P., Phan, S.C., Shames, D.S., Cunningham, D., METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2−) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). J. Clin. Oncol., 33(Suppl. 15), 2015, 4012.
33. Shimoyama, R., Yasui, H., Boku, N., Onozawa, Y., Hironaka, S., Fukutomi, A., et al. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer 12:4 (2009), 206–211, 10.1007/s10120-009-0524-9 Epub 2010 January 5.
34. Tarazona, N., Smyth, E.C., Peckit, C., Chau, I., Watkins, D., Rao, S., et al. Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. Ther. Adv. Med. Oncol. 8:March (2) (2016), 104–112, 10.1177/1758834015621669.
35. The Nordic Cochrane Centre, The Cochrane Collaboration, Review Manager (RevMan). 5.3. 2014, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
36. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin. 65:March (2) (2015), 87–108, 10.3322/caac.21262 Epub 2015 February 4.
37. Wagner, A.D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev., 17(March (3)), 2010, CD004064, 10.1002/14651858.CD004064.pub3.
38. Wilke, H., Muro, K., Van Cutsem, E., Oh, S.C., Bodoky, G., Shimada, Y., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15:October (11) (2014), 1224–1235, 10.1016/S1470-2045(14)70420-6 Epub 2014 September 17.